Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17559454 | 0.98 | SMN1; SMN2 (0.65) | SMN1; SMN2GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL7121916 | 0.91 | SMN1; SMN2 (0.77) | SMN1; SMN2GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL20567427 | 0.87 | ALDH1A1 (0.61) | SMN1; SMN2GAAALDH1A1TSHRKMT2A | |
| SCHEMBL30281137 | 0.85 | MGLL (0.63) | SMN1; SMN2GAAALDH1A1NPSR1TP53 | |
| SCHEMBL20267430 | 0.84 | GAA (0.73) | SMN1; SMN2GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL3226592 | 0.84 | ALDH1A1 (0.55) | SMN1; SMN2GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL6474889 | 0.84 | TSHR (0.59) | SMN1; SMN2GAAALDH1A1TSHRKMT2A | |
| (2-Aminophenyl)(Morpholino)Methanone SCHEMBL11446442 | 0.83 | GAA (0.62) | SMN1; SMN2GAAALDH1A1TSHRNPSR1 | |
| (2-Aminophenyl)(Morpholino)Methanone SCHEMBL30988542 | 0.83 | GAA (0.62) | SMN1; SMN2GAAALDH1A1TSHRNPSR1 | |
| SCHEMBL1583125 | 0.82 | SMN1; SMN2 (0.59) | SMN1; SMN2GAAALDH1A1TSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676600-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | Deliver Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024186579-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF | DELIVER THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | WO | disclosed |
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC | 2007-09-13 | — | — | US | disclosed |
| US-7214715-B2 | Compounds to treat Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1025095-A1 | SUBSTITUTED CHROMAN DERIVATIVES | AstraZeneca AB (SE) | 2000-08-09 | — | — | EP | disclosed |
| WO-1999014212-A1 | SUBSTITUTED CHROMAN DERIVATIVES | ASTRAZENECA AB (SE) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213407-A1 | Compounds to treat Alzheimer's disease | PSEN2, PSEN1, CHAT | SMN1; SMN2 539/4885GAA 57/4885ALDH1A1 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.